Selected Publications

Stashwick, Czernieck BJ, Tanyi JL: Dendritic Cell Vaccine Therapy for Ovarian Cancer Chapter. Ovarian Cancer Immunotherapy: Current Perspectives. Farghaly SA (eds.). Oxford University Press, New York, NY, Chpt 8, 2018.

O'Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. Immunotherapy 9(9):767-780, Aug 2017.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH: Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. J Immunotherapy 40(3):104-107, Apr 2017.

Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr: Tumor regression and delayed onset toxicity following B7-H4 CAR T cell Therapy. Mol Ther 24(11):1987-1999, Nov 2016.

Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Schmitz K: Race-based disparities in loss of functional independence after hysterectomy for uterine cancer. Support Care Cancer 24(8):3573-80, Aug 2016.

O’Hara M, Stashwick C, Haas AR, Tanyi JL: Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8(4):449-60, 2016.

Urbanksa K, Stashwick C, Powell DJ: Follicle-stimulating hormone receptor as a target in the redirected T-cell therapy for cancer. Cancer Immunology Research 3(10):1130-7, Oct 2015.

Urbanska K, Lynn R, Stashwick C, Thakur A, Lum L, Powell DJ: Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med 13;12:347, Dec 2014.

Smith J*, Stashwick C*, Powell DJ (*co-first authors): B7-H4 as a potential target for immunotherapy for gynecologic cancer: A closer look. Gynecol Oncol 134(1):181-189, 2014.

Stashwick C, Post MD, Arruda JS, Spillman, MA, Behbakht K, Davidson SA, Kelly MG: Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer 21(8):1422-7, Nov 2011.